To construct preventive and therapeutic strategy in cardiovascular diseases, we have applied linkage analyses in novel cardiovascular biomarkers in stage A or B and C patients. Even in patients with stable coronary artery disease, severity of SAS (AHI) significantly correlated with elevation of Hs-TnT, BNP, and sLOX-1 (detection of minor myocardial injury : MMI and silent vulnerable plaque). Elevation of sLOX-1 was characterized by ruptured thin-cap fibroatheroma. Strong statin therapy lowered Hs-TnT (deterrent of MMI) and attenuated periprocedural myocardial injury following PCI. Concerning the MMI in chronic heart failure, we revealed cross-talk between MMI and serum cholesterol levels and production of monocyte pro-inflammatory cytokines. It is important to select and set the high-precision surrogate biomarkers according to the heart failure stages and construct the comprehensive therapeutic strategies.